Lance Berberian on company mission
From Lance Berberian - The Impact of Technology on New Healthcare Models (1/31/2019) · · NCState
“We have an important mission that affects many people: we will improve health and improve lives and we will do it by three ways — we are going to focus on world-class diagnostics, we are going to bring innovative medicines to patients who need them sooner, and we're gonna use technology to improve the delivery of care.”
On , Lance Berberian, Former Executive Vice President and Chief Information & Technology Officer at Laboratory Corporation of Amerc Holdings, spoke about company mission during Lance Berberian - The Impact of Technology on New Healthcare Models (1/31/2019) on NCState.
About Lance Berberian
Lance Berberian, former Executive Vice President and Chief Information & Technology Officer at Labcorp, spoke in January 2019 about the company's use of technology to transform healthcare. He described Labcorp's mission as improving health and lives through world-class diagnostics, bringing innovative medicines to patients sooner, and using technology to improve care delivery. Berberian noted that from 2014 to 2018, 46 percent of Labcorp's capital investments went into IT. He identified cybersecurity as a primary concern, stating that it was the fastest-growing part of the IT budget and that the company was applying artificial intelligence to identify zero-day attacks. Berberian discussed Labcorp's role in precision medicine, including genetic testing such as germline testing for inherited variants and oncology testing for cancer mutations. He cited the example of the BRCA variant, which he said raises breast cancer risk from 3 percent to 54 percent for women who have it. He also mentioned Labcorp's non-invasive prenatal test, which analyzes fetal DNA from a maternal blood sample. Berberian characterized the U.S. healthcare reimbursement system as "incredibly complex," noting that there are more lines of code in Labcorp's billing system than in its lab system. He added that while laboratory testing accounts for 3 percent of healthcare spending, it influences 85 percent of care decisions.